CEO and CFO Resign Abruptly, Citing Change in Control; Interim Leadership Named
BRTX has more than doubled off its 52-week low of $0.159 on light trading volume (0.1× avg).
Summary
CEO Lance Alstodt and CFO Robert Kristal resigned effective July 13, 2026, asserting 'Good Reason' based on an alleged Change in Control — a clause that typically triggers severance. Director Katharyn Field steps in as interim CEO and interim CFO, while director David Rosa also resigned from the board. Two new directors, Esha Randhawa and Steven Brown, were elected to fill vacancies. This follows activist Kaos Capital's 4.9% stake and push for a meeting in late May, and comes just weeks after the company extended the executives' employment agreements. The sudden departure of both top financial officers amid a control dispute raises serious governance and stability concerns for a micro-cap biotech with a Phase 2 trial underway.
At the time of this announcement, BRTX was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.16 to $1.89. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.